Profile - To The Moon

lyner

Posts · 11Posts · 11
Following · 0Following · 0
Followers · 0Followers · 0

- lynerlyner
  ·2021-08-22
  Like!!
  U.S. stocks close higher in Nasdaq-led rally, but still see losses for the week
  MW U.S. stocks close higher in Nasdaq-led rally, but still see losses for the week By Christine
  U.S. stocks close higher in Nasdaq-led rally, but still see losses for the week
  393 Comment
  1
  Share
  Report
- lynerlyner
  ·2021-08-22
  Like!
  People in the U.S. who received Moderna's or Pfizer's COVID-19 vaccine will be eligible for a booster dose in September
  MW People in the U.S. who received Moderna's or Pfizer's COVID-19 vaccine will be eligible for a boo
  People in the U.S. who received Moderna's or Pfizer's COVID-19 vaccine will be eligible for a booster dose in September
  299 Comment
  Like
  Share
  Report
- lynerlyner
  ·2021-08-22
  Like!
  COVID SCIENCE-Sugary molecules may be one way to prevent COVID; patients getting younger
  By Nancy Lapid Aug 20 (Reuters) - Here is a summary of some recent studies on COVID-19. They inclu
  COVID SCIENCE-Sugary molecules may be one way to prevent COVID; patients getting younger
  302 1
  1
  Share
  Report
- lynerlyner
  ·2021-08-21
  Like!
  Sorry, this post has been deleted
  125 Comment
  1
  Share
  Report
- lynerlyner
  ·2021-08-21
  Like!
  Sorry, this post has been deleted
  354 Comment
  Like
  Share
  Report
- lynerlyner
  ·2021-08-19
  Interestinggg
  Investors compare 2021 stock-market rally to the pre-crash summer of 1987 — should they?
  ‘Strength often begets strength,’ but there’s no guarantee 'Wall Street' in the pre-working from hom
  Investors compare 2021 stock-market rally to the pre-crash summer of 1987 — should they?
  432 Comment
  1
  Share
  Report
- lynerlyner
  ·2021-08-19
  Yesss
  3 Reasons Why Nio Is Rebounding From 6-Session Losing Streak
  Nio, Inc. shares gained ground Wednesday, reversing course from the declines seen in the previous si
  3 Reasons Why Nio Is Rebounding From 6-Session Losing Streak
  280 Comment
  1
  Share
  Report
- lynerlyner
  ·2021-06-15
  $Fortuna Silver Mines(FSM)$hopefully it goes back up
  426 Comment
  1
  Share
  Report
- lynerlyner
  ·2021-06-15
  Interestingggg
  Sorry, this post has been deleted
  285 Comment
  Like
  Share
  Report
- lynerlyner
  ·2021-06-02
  $Hyliion Holdings Corp.(HYLN)$it's moving
  692 1
  Like
  Share
  Report
No following yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3579171197354301","uuid":"3579171197354301","gmtCreate":1616077173584,"gmtModify":1622113531374,"name":"lyner","pinyin":"lyner","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/0b4cf00eeb2342a1bc5d6a42a6f98f6d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":27,"tweetSize":11,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":832958932,"gmtCreate":1629565848926,"gmtModify":1676530071439,"author":{"id":"3579171197354301","authorId":"3579171197354301","name":"lyner","avatar":"https://static.tigerbbs.com/0b4cf00eeb2342a1bc5d6a42a6f98f6d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579171197354301","idStr":"3579171197354301"},"themes":[],"htmlText":"Like!!","listText":"Like!!","text":"Like!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/832958932","repostId":"2161416717","repostType":2,"repost":{"id":"2161416717","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629556440,"share":"https://ttm.financial/m/news/2161416717?lang=&edition=fundamental","pubTime":"2021-08-21 22:34","market":"hk","language":"en","title":"U.S. stocks close higher in Nasdaq-led rally, but still see losses for the week","url":"https://stock-news.laohu8.com/highlight/detail?id=2161416717","media":"Dow Jones","summary":"MW U.S. stocks close higher in Nasdaq-led rally, but still see losses for the week\n\n\n  By Christine ","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW U.S. stocks close higher in Nasdaq-led rally, but still see losses for the week\n</p>\n<p>\n  By Christine Idzelis and Mark DeCambre \n</p>\n<p>\n  U.S. stock indexes closed higher Friday, but still ended with losses for the week on fears over the spread of the coronavirus delta variant, the imminent tapering of Federal Reserve bond buying, and China's restrictions on its economy. \n</p>\n<p>\n  Friday's recovery was broad, with technology stocks among the leaders in the S&amp;P 500 and even energy catching a bid after a withering week for the sector as oil prices slumped. \n</p>\n<p>\n  How did benchmarks trade? \n</p>\n<p>\n  On Thursday, major markets ended mixed, with the S&amp;P 500 and Nasdaq Composite registering small gains, while the small-cap Russell 2000 ended 1.2% lower. \n</p>\n<p>\n  For the week, the S&amp;P 500 slid 0.6%, the Dow declined 1.1% and the Nasdaq Composite lost 0.7% , while the small-cap Russell 2000 index  fell 2.5%. \n</p>\n<p>\n  What drove markets? \n</p>\n<p>\n  Buy the dip for the week was in play on Friday, with investors scooping up shares of information technology  and turning to embattled energy  and financials , among the worst weekly performers. \n</p>\n<p>\n  \"The tidal wave of liquidity is so powerful, so vast, that the buy-the-dips mentality is the dominant force right now,\" said David Donabedian, chief investment officer of CIBC Private Wealth Management, in a phone interview Friday. Information technology and communication services are among the areas leading the market in Friday's trading, he said, similar to last year when COVID-19 was \"raging\" and \"stay-at-home stocks\" topped the charts. \n</p>\n<p>\n  The energy sector fell 7.3% this week, while financials were off 2.3%, FactSet data show. Consumer staples  were up 0.4% for the week, healthcare  climbed 1.8%, and utilities  gained 1.8%, which are largely defensive plays. Technology, meanwhile, erased its weekly slide. \n</p>\n<p>\n  \"It's a little difficult to get too excited about equities,\" particularly U.S. large-cap, as valuations are \"pretty full,\" said Michael Reynolds, vice president of investment strategy at wealth-management firm Glenmede, in a phone interview Friday. But Glenmede still has an appetite for risk, he said, targeting  areas such as small-cap and international stocks as well as real estate investment trusts. \n</p>\n<p>\n  Researchers at Capital Economics said that delta's spread continues to weigh on prices, particularly in the commodity complex. \"Commodity prices mostly fell this week on the back of a stronger U.S. dollar as well as mounting concerns over the demand outlook,\" Capital Economics economists wrote in a Friday note. \n</p>\n<p>\n  All week, concerns about a sharp rise in U.S. COVID cases, hospitalizations and deaths have tamped down bullishness, as the daily average of new U.S. cases over the past seven days rose to 143,827 as of Thursday, up 44% from two weeks ago and the most since Feb. 1, according to a New York Times tracker . \n</p>\n<p>\n  The change in the complexion of the viral spread is causing some Fed members to rethink tapering strategies. \n</p>\n<p>\n  Indeed, Dallas Federal Reserve President Rob Kaplan said he may reconsider  his call for the central bank to quickly start to taper its monthly buying of $120 billion in Treasury and mortgage-backed securities if it looks like the spread of the coronavirus delta variant is slowing economic growth. \n</p>\n<p>\n  \"It is in all of our interest to slow the spread, and right now we're in a negative trend,\" Kaplan said in an interview with Fox Business Network  on Friday. Kaplan said the delta variant has caused him to have an open mind about the path of monetary policy. He called the delta variant \"the big imponderable\" in the outlook. \n</p>\n<p>\n  The remarks from Kaplan, who is a \"more hawkish\" Fed official, may be contributing to the market's rise Friday, according to Donabedian. Just a couple of days ago, the release of the Fed policy meeting minutes had indicated  \"consensus to begin tapering this year,\" he said, and some investors may now see the possibility that the central bank could \"adjust its thinking.\" \n</p>\n<p>\n  \"What we've been telling clients is the first half of the year was nirvana,\" with above-average gains and \"very low market volatility,\" said Baltimore-based Donabedian of CIBC Private Wealth. \"We're in a bull market, but it's going to be a tougher slog over the second half of the year.\" \n</p>\n<p>\n  The Cboe Volatility Index, often referred to by its ticker symbol VIX, a measure of implied stock market volatility, jumped in the early hours Friday, while the U.S. dollar  reached a fresh nine-month high. The VIX  was about 15% lower around the end of trading Friday, according to FactSet data. \n</p>\n<p>\n  Which companies were in focus? \n</p>\n<p>\n  How did other assets fare? \n</p>\n<p>\n  --Steve Goldstein contributed to the report. \n</p>\n<p>\n  -Christine Idzelis \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 21, 2021 10:34 ET (14:34 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. stocks close higher in Nasdaq-led rally, but still see losses for the week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. stocks close higher in Nasdaq-led rally, but still see losses for the week\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-21 22:34</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW U.S. stocks close higher in Nasdaq-led rally, but still see losses for the week\n</p>\n<p>\n  By Christine Idzelis and Mark DeCambre \n</p>\n<p>\n  U.S. stock indexes closed higher Friday, but still ended with losses for the week on fears over the spread of the coronavirus delta variant, the imminent tapering of Federal Reserve bond buying, and China's restrictions on its economy. \n</p>\n<p>\n  Friday's recovery was broad, with technology stocks among the leaders in the S&amp;P 500 and even energy catching a bid after a withering week for the sector as oil prices slumped. \n</p>\n<p>\n  How did benchmarks trade? \n</p>\n<p>\n  On Thursday, major markets ended mixed, with the S&amp;P 500 and Nasdaq Composite registering small gains, while the small-cap Russell 2000 ended 1.2% lower. \n</p>\n<p>\n  For the week, the S&amp;P 500 slid 0.6%, the Dow declined 1.1% and the Nasdaq Composite lost 0.7% , while the small-cap Russell 2000 index  fell 2.5%. \n</p>\n<p>\n  What drove markets? \n</p>\n<p>\n  Buy the dip for the week was in play on Friday, with investors scooping up shares of information technology  and turning to embattled energy  and financials , among the worst weekly performers. \n</p>\n<p>\n  \"The tidal wave of liquidity is so powerful, so vast, that the buy-the-dips mentality is the dominant force right now,\" said David Donabedian, chief investment officer of CIBC Private Wealth Management, in a phone interview Friday. Information technology and communication services are among the areas leading the market in Friday's trading, he said, similar to last year when COVID-19 was \"raging\" and \"stay-at-home stocks\" topped the charts. \n</p>\n<p>\n  The energy sector fell 7.3% this week, while financials were off 2.3%, FactSet data show. Consumer staples  were up 0.4% for the week, healthcare  climbed 1.8%, and utilities  gained 1.8%, which are largely defensive plays. Technology, meanwhile, erased its weekly slide. \n</p>\n<p>\n  \"It's a little difficult to get too excited about equities,\" particularly U.S. large-cap, as valuations are \"pretty full,\" said Michael Reynolds, vice president of investment strategy at wealth-management firm Glenmede, in a phone interview Friday. But Glenmede still has an appetite for risk, he said, targeting  areas such as small-cap and international stocks as well as real estate investment trusts. \n</p>\n<p>\n  Researchers at Capital Economics said that delta's spread continues to weigh on prices, particularly in the commodity complex. \"Commodity prices mostly fell this week on the back of a stronger U.S. dollar as well as mounting concerns over the demand outlook,\" Capital Economics economists wrote in a Friday note. \n</p>\n<p>\n  All week, concerns about a sharp rise in U.S. COVID cases, hospitalizations and deaths have tamped down bullishness, as the daily average of new U.S. cases over the past seven days rose to 143,827 as of Thursday, up 44% from two weeks ago and the most since Feb. 1, according to a New York Times tracker . \n</p>\n<p>\n  The change in the complexion of the viral spread is causing some Fed members to rethink tapering strategies. \n</p>\n<p>\n  Indeed, Dallas Federal Reserve President Rob Kaplan said he may reconsider  his call for the central bank to quickly start to taper its monthly buying of $120 billion in Treasury and mortgage-backed securities if it looks like the spread of the coronavirus delta variant is slowing economic growth. \n</p>\n<p>\n  \"It is in all of our interest to slow the spread, and right now we're in a negative trend,\" Kaplan said in an interview with Fox Business Network  on Friday. Kaplan said the delta variant has caused him to have an open mind about the path of monetary policy. He called the delta variant \"the big imponderable\" in the outlook. \n</p>\n<p>\n  The remarks from Kaplan, who is a \"more hawkish\" Fed official, may be contributing to the market's rise Friday, according to Donabedian. Just a couple of days ago, the release of the Fed policy meeting minutes had indicated  \"consensus to begin tapering this year,\" he said, and some investors may now see the possibility that the central bank could \"adjust its thinking.\" \n</p>\n<p>\n  \"What we've been telling clients is the first half of the year was nirvana,\" with above-average gains and \"very low market volatility,\" said Baltimore-based Donabedian of CIBC Private Wealth. \"We're in a bull market, but it's going to be a tougher slog over the second half of the year.\" \n</p>\n<p>\n  The Cboe Volatility Index, often referred to by its ticker symbol VIX, a measure of implied stock market volatility, jumped in the early hours Friday, while the U.S. dollar  reached a fresh nine-month high. The VIX  was about 15% lower around the end of trading Friday, according to FactSet data. \n</p>\n<p>\n  Which companies were in focus? \n</p>\n<p>\n  How did other assets fare? \n</p>\n<p>\n  --Steve Goldstein contributed to the report. \n</p>\n<p>\n  -Christine Idzelis \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 21, 2021 10:34 ET (14:34 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF","UPRO":"三倍做多标普500ETF",".SPX":"S&P 500 Index","SPXU":"三倍做空标普500ETF","OEF":"标普100指数ETF-iShares","SDS":"两倍做空标普500ETF","OEX":"标普100","SH":"标普500反向ETF","IVV":"标普500指数ETF","SSO":"两倍做多标普500ETF"},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161416717","content_text":"MW U.S. stocks close higher in Nasdaq-led rally, but still see losses for the week\n\n\n  By Christine Idzelis and Mark DeCambre \n\n\n  U.S. stock indexes closed higher Friday, but still ended with losses for the week on fears over the spread of the coronavirus delta variant, the imminent tapering of Federal Reserve bond buying, and China's restrictions on its economy. \n\n\n  Friday's recovery was broad, with technology stocks among the leaders in the S&P 500 and even energy catching a bid after a withering week for the sector as oil prices slumped. \n\n\n  How did benchmarks trade? \n\n\n  On Thursday, major markets ended mixed, with the S&P 500 and Nasdaq Composite registering small gains, while the small-cap Russell 2000 ended 1.2% lower. \n\n\n  For the week, the S&P 500 slid 0.6%, the Dow declined 1.1% and the Nasdaq Composite lost 0.7% , while the small-cap Russell 2000 index  fell 2.5%. \n\n\n  What drove markets? \n\n\n  Buy the dip for the week was in play on Friday, with investors scooping up shares of information technology  and turning to embattled energy  and financials , among the worst weekly performers. \n\n\n  \"The tidal wave of liquidity is so powerful, so vast, that the buy-the-dips mentality is the dominant force right now,\" said David Donabedian, chief investment officer of CIBC Private Wealth Management, in a phone interview Friday. Information technology and communication services are among the areas leading the market in Friday's trading, he said, similar to last year when COVID-19 was \"raging\" and \"stay-at-home stocks\" topped the charts. \n\n\n  The energy sector fell 7.3% this week, while financials were off 2.3%, FactSet data show. Consumer staples  were up 0.4% for the week, healthcare  climbed 1.8%, and utilities  gained 1.8%, which are largely defensive plays. Technology, meanwhile, erased its weekly slide. \n\n\n  \"It's a little difficult to get too excited about equities,\" particularly U.S. large-cap, as valuations are \"pretty full,\" said Michael Reynolds, vice president of investment strategy at wealth-management firm Glenmede, in a phone interview Friday. But Glenmede still has an appetite for risk, he said, targeting  areas such as small-cap and international stocks as well as real estate investment trusts. \n\n\n  Researchers at Capital Economics said that delta's spread continues to weigh on prices, particularly in the commodity complex. \"Commodity prices mostly fell this week on the back of a stronger U.S. dollar as well as mounting concerns over the demand outlook,\" Capital Economics economists wrote in a Friday note. \n\n\n  All week, concerns about a sharp rise in U.S. COVID cases, hospitalizations and deaths have tamped down bullishness, as the daily average of new U.S. cases over the past seven days rose to 143,827 as of Thursday, up 44% from two weeks ago and the most since Feb. 1, according to a New York Times tracker . \n\n\n  The change in the complexion of the viral spread is causing some Fed members to rethink tapering strategies. \n\n\n  Indeed, Dallas Federal Reserve President Rob Kaplan said he may reconsider  his call for the central bank to quickly start to taper its monthly buying of $120 billion in Treasury and mortgage-backed securities if it looks like the spread of the coronavirus delta variant is slowing economic growth. \n\n\n  \"It is in all of our interest to slow the spread, and right now we're in a negative trend,\" Kaplan said in an interview with Fox Business Network  on Friday. Kaplan said the delta variant has caused him to have an open mind about the path of monetary policy. He called the delta variant \"the big imponderable\" in the outlook. \n\n\n  The remarks from Kaplan, who is a \"more hawkish\" Fed official, may be contributing to the market's rise Friday, according to Donabedian. Just a couple of days ago, the release of the Fed policy meeting minutes had indicated  \"consensus to begin tapering this year,\" he said, and some investors may now see the possibility that the central bank could \"adjust its thinking.\" \n\n\n  \"What we've been telling clients is the first half of the year was nirvana,\" with above-average gains and \"very low market volatility,\" said Baltimore-based Donabedian of CIBC Private Wealth. \"We're in a bull market, but it's going to be a tougher slog over the second half of the year.\" \n\n\n  The Cboe Volatility Index, often referred to by its ticker symbol VIX, a measure of implied stock market volatility, jumped in the early hours Friday, while the U.S. dollar  reached a fresh nine-month high. The VIX  was about 15% lower around the end of trading Friday, according to FactSet data. \n\n\n  Which companies were in focus? \n\n\n  How did other assets fare? \n\n\n  --Steve Goldstein contributed to the report. \n\n\n  -Christine Idzelis \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  August 21, 2021 10:34 ET (14:34 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":393,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832951426,"gmtCreate":1629565818265,"gmtModify":1676530071431,"author":{"id":"3579171197354301","authorId":"3579171197354301","name":"lyner","avatar":"https://static.tigerbbs.com/0b4cf00eeb2342a1bc5d6a42a6f98f6d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579171197354301","idStr":"3579171197354301"},"themes":[],"htmlText":"Like!","listText":"Like!","text":"Like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/832951426","repostId":"2161640741","repostType":2,"repost":{"id":"2161640741","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1629556200,"share":"https://ttm.financial/m/news/2161640741?lang=&edition=fundamental","pubTime":"2021-08-21 22:30","market":"hk","language":"en","title":"People in the U.S. who received Moderna's or Pfizer's COVID-19 vaccine will be eligible for a booster dose in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2161640741","media":"Dow Jones","summary":"MW People in the U.S. who received Moderna's or Pfizer's COVID-19 vaccine will be eligible for a boo","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW People in the U.S. who received Moderna's or Pfizer's COVID-19 vaccine will be eligible for a booster dose in September\n</p>\n<p>\n  Jaimy Lee \n</p>\n<p>\n  President Biden addressed Americans on Tuesday, saying 'it will be easy' \n</p>\n<p>\n  Federal health officials said Wednesday that a third dose of the COVID-19 shots developed by Moderna Inc. and Pfizer Inc. will be available in mid-September for Americans who have been fully vaccinated for at least eight months. \n</p>\n<p>\n  They cited waning protection as the reason for a booster shot. \n</p>\n<p>\n  \"The available data make very clear that protection against SARS-CoV-2 infection begins to decrease over time following the initial doses of vaccination, and in association with the dominance of the delta variant, we are starting to see evidence of reduced protection against mild and moderate disease,\" the officials said in a statement . \n</p>\n<p>\n  The new plan to administer COVID-19 boosters to Americans is subject to evaluation from the Food and Drug Administration and a recommendation from a Centers for Disease Control and Prevention committee. \n</p>\n<p>\n  It does not apply to people who got the Johnson &amp; Johnson <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> vaccine, only those who received the vaccines developed by Moderna <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> and Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a>. \n</p>\n<p>\n  Officials said individuals who got J&amp;J's single-dose vaccine will likely need boosters, but they are waiting for data from the company in the coming weeks and then will set out a plan. \n</p>\n<p>\n  For the people who received the mRNA vaccines, boosters will begin to be available on Sept. 20. The first people to qualify for a third dose will include \"many health care providers, nursing home residents, and other seniors,\" then \"residents of long-term care facilities.\" \n</p>\n<p>\n  Related: Who can get a COVID booster shot, and where do you get <a href=\"https://laohu8.com/S/AONE.U\">one</a>? Here's what we know so far  \n</p>\n<p>\n  The months-long debate about whether Americans who have been vaccinated will need an extra dose has been seemingly blunted by the rapid spread of the delta variant and the ensuing rise of cases, hospitalizations, and deaths in the U.S. over the last month or so. \n</p>\n<p>\n  Delta, which is more than twice as infectious as the original strain of the virus, is now estimated by the Centers for Disease Control and Prevention  to make up nearly 99% of all recent cases here. \n</p>\n<p>\n  \"Eight months after your second shot, get a booster shot,\" President Joe Biden said Wednesday . \"It will be easy. Just show your vaccination card and you'll get a booster -- no other ID, no insurance, no state residency requirement.\" \n</p>\n<p>\n  There are several factors at play in the booster discussion , but these are some of the most pressing questions: Do people who have been fully vaccinated actually need a boost? Is it ethical to give Americans a second or third dose when much of the world have no access to vaccines? Will Americans who have been told by federal health officials many times that boosters aren't needed listen this time? \n</p>\n<p>\n  When the U.S. last week said it would allow people who are immunocompromised to get an extra shot, officials repeated that boosters for the general public are not needed at this time . \n</p>\n<p>\n  \"We do not believe that others--elderly or non-elderly who are not immunocompromised--need a vaccine right at this moment, but this is a dynamic process and the data will be evaluated,\" Dr. Anthony Fauci, Biden's chief medical adviser, told reporters last Thursday. \n</p>\n<p>\n  That said, it's thought that immunity is waning among the vaccinated , and that's why we're hearing about more breakthrough infections, though those cases are still considered rare. \n</p>\n<p>\n  Texas Gov. Greg Abbott  is the most notable example this week of someone who is fully vaccinated who has also tested positive for the virus. \n</p>\n<p>\n  There is no federal tally of breakthrough cases, a decision that has been criticized by some pandemic experts , but some states are publicly sharing the data they have about these infections. \n</p>\n<p>\n  As of Aug. 8, 0.3% of Californians  that 0.2% people in the state--or 9,969 people out of the 4.3 million who have been fully vaccinated--have reported breakthrough infections, according to media reports. About 450 of those individuals were hospitalized, and 105 people died. \n</p>\n<p>\n  Don't miss from WSJ: As Delta surges, COVID-19 breakthrough cases remain uncommon  \n</p>\n<p>\n  Here's what the numbers say \n</p>\n<p>\n  The seven-day moving average is 128,347 cases per day and 553 deaths per day, as of Aug. 16, according to the latest data  from the Centers for Disease Control and Prevention. \n</p>\n<p>\n  August has been the worst month in 2021 for new cases since February, according to USA Today  found that there were more than 1,000 COVID-19 deaths on Tuesday. \n</p>\n<p>\n  About 168.9 million people  in the U.S., or 50.9% of the total population, are now fully vaccinated, as of Aug. 17, and 198.7 million, or 70.1%, of those who qualify for the vaccine, have received at least one shot. \n</p>\n<p>\n  Here's what else you need to know about COVID-19 \n</p>\n<p>\n  -- The U.S. extended the transit-related mask mandate  \n</p>\n<p>\n  -- COVID-19 vaccination rates are ticking up in Latin America, where it's more common for people to trust vaccines, according to The Wall Street Journal . In Chile and Uruguay, about two-thirds of the population in both countries are fully vaccinated. \n</p>\n<p>\n  -- Roche Holding AG said Actemra , its rheumatoid arthritis drug that recently received authorization in the U.S. as a COVID-19 treatment for hospitalized patients, is in short supply and will be so for weeks or months. The drug is being used around worldwide; however, demand for Actemra in the U.S. is \"well beyond 400% of pre-COVID levels over the last two weeks alone,\" the drug maker said Monday. Actemra, which is an IL-6 inhibitor, is one of the few therapies that has demonstrated its value as a COVID-19 treatment for the severely ill. \n</p>\n<p>\n  -Jaimy Lee \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 21, 2021 10:30 ET (14:30 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>People in the U.S. who received Moderna's or Pfizer's COVID-19 vaccine will be eligible for a booster dose in September</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPeople in the U.S. who received Moderna's or Pfizer's COVID-19 vaccine will be eligible for a booster dose in September\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-08-21 22:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<p>\nMW People in the U.S. who received Moderna's or Pfizer's COVID-19 vaccine will be eligible for a booster dose in September\n</p>\n<p>\n  Jaimy Lee \n</p>\n<p>\n  President Biden addressed Americans on Tuesday, saying 'it will be easy' \n</p>\n<p>\n  Federal health officials said Wednesday that a third dose of the COVID-19 shots developed by Moderna Inc. and Pfizer Inc. will be available in mid-September for Americans who have been fully vaccinated for at least eight months. \n</p>\n<p>\n  They cited waning protection as the reason for a booster shot. \n</p>\n<p>\n  \"The available data make very clear that protection against SARS-CoV-2 infection begins to decrease over time following the initial doses of vaccination, and in association with the dominance of the delta variant, we are starting to see evidence of reduced protection against mild and moderate disease,\" the officials said in a statement . \n</p>\n<p>\n  The new plan to administer COVID-19 boosters to Americans is subject to evaluation from the Food and Drug Administration and a recommendation from a Centers for Disease Control and Prevention committee. \n</p>\n<p>\n  It does not apply to people who got the Johnson &amp; Johnson <a href=\"https://laohu8.com/S/JNJ\">$(JNJ)$</a> vaccine, only those who received the vaccines developed by Moderna <a href=\"https://laohu8.com/S/MRNA\">$(MRNA)$</a> and Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a>. \n</p>\n<p>\n  Officials said individuals who got J&amp;J's single-dose vaccine will likely need boosters, but they are waiting for data from the company in the coming weeks and then will set out a plan. \n</p>\n<p>\n  For the people who received the mRNA vaccines, boosters will begin to be available on Sept. 20. The first people to qualify for a third dose will include \"many health care providers, nursing home residents, and other seniors,\" then \"residents of long-term care facilities.\" \n</p>\n<p>\n  Related: Who can get a COVID booster shot, and where do you get <a href=\"https://laohu8.com/S/AONE.U\">one</a>? Here's what we know so far  \n</p>\n<p>\n  The months-long debate about whether Americans who have been vaccinated will need an extra dose has been seemingly blunted by the rapid spread of the delta variant and the ensuing rise of cases, hospitalizations, and deaths in the U.S. over the last month or so. \n</p>\n<p>\n  Delta, which is more than twice as infectious as the original strain of the virus, is now estimated by the Centers for Disease Control and Prevention  to make up nearly 99% of all recent cases here. \n</p>\n<p>\n  \"Eight months after your second shot, get a booster shot,\" President Joe Biden said Wednesday . \"It will be easy. Just show your vaccination card and you'll get a booster -- no other ID, no insurance, no state residency requirement.\" \n</p>\n<p>\n  There are several factors at play in the booster discussion , but these are some of the most pressing questions: Do people who have been fully vaccinated actually need a boost? Is it ethical to give Americans a second or third dose when much of the world have no access to vaccines? Will Americans who have been told by federal health officials many times that boosters aren't needed listen this time? \n</p>\n<p>\n  When the U.S. last week said it would allow people who are immunocompromised to get an extra shot, officials repeated that boosters for the general public are not needed at this time . \n</p>\n<p>\n  \"We do not believe that others--elderly or non-elderly who are not immunocompromised--need a vaccine right at this moment, but this is a dynamic process and the data will be evaluated,\" Dr. Anthony Fauci, Biden's chief medical adviser, told reporters last Thursday. \n</p>\n<p>\n  That said, it's thought that immunity is waning among the vaccinated , and that's why we're hearing about more breakthrough infections, though those cases are still considered rare. \n</p>\n<p>\n  Texas Gov. Greg Abbott  is the most notable example this week of someone who is fully vaccinated who has also tested positive for the virus. \n</p>\n<p>\n  There is no federal tally of breakthrough cases, a decision that has been criticized by some pandemic experts , but some states are publicly sharing the data they have about these infections. \n</p>\n<p>\n  As of Aug. 8, 0.3% of Californians  that 0.2% people in the state--or 9,969 people out of the 4.3 million who have been fully vaccinated--have reported breakthrough infections, according to media reports. About 450 of those individuals were hospitalized, and 105 people died. \n</p>\n<p>\n  Don't miss from WSJ: As Delta surges, COVID-19 breakthrough cases remain uncommon  \n</p>\n<p>\n  Here's what the numbers say \n</p>\n<p>\n  The seven-day moving average is 128,347 cases per day and 553 deaths per day, as of Aug. 16, according to the latest data  from the Centers for Disease Control and Prevention. \n</p>\n<p>\n  August has been the worst month in 2021 for new cases since February, according to USA Today  found that there were more than 1,000 COVID-19 deaths on Tuesday. \n</p>\n<p>\n  About 168.9 million people  in the U.S., or 50.9% of the total population, are now fully vaccinated, as of Aug. 17, and 198.7 million, or 70.1%, of those who qualify for the vaccine, have received at least one shot. \n</p>\n<p>\n  Here's what else you need to know about COVID-19 \n</p>\n<p>\n  -- The U.S. extended the transit-related mask mandate  \n</p>\n<p>\n  -- COVID-19 vaccination rates are ticking up in Latin America, where it's more common for people to trust vaccines, according to The Wall Street Journal . In Chile and Uruguay, about two-thirds of the population in both countries are fully vaccinated. \n</p>\n<p>\n  -- Roche Holding AG said Actemra , its rheumatoid arthritis drug that recently received authorization in the U.S. as a COVID-19 treatment for hospitalized patients, is in short supply and will be so for weeks or months. The drug is being used around worldwide; however, demand for Actemra in the U.S. is \"well beyond 400% of pre-COVID levels over the last two weeks alone,\" the drug maker said Monday. Actemra, which is an IL-6 inhibitor, is one of the few therapies that has demonstrated its value as a COVID-19 treatment for the severely ill. \n</p>\n<p>\n  -Jaimy Lee \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 21, 2021 10:30 ET (14:30 GMT)\n</p>\n<p>\n  Copyright (c) 2021 Dow Jones &amp; Company, Inc.\n</p>\n</font></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生","PFE":"辉瑞","MRNA":"Moderna, Inc."},"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161640741","content_text":"MW People in the U.S. who received Moderna's or Pfizer's COVID-19 vaccine will be eligible for a booster dose in September\n\n\n  Jaimy Lee \n\n\n  President Biden addressed Americans on Tuesday, saying 'it will be easy' \n\n\n  Federal health officials said Wednesday that a third dose of the COVID-19 shots developed by Moderna Inc. and Pfizer Inc. will be available in mid-September for Americans who have been fully vaccinated for at least eight months. \n\n\n  They cited waning protection as the reason for a booster shot. \n\n\n  \"The available data make very clear that protection against SARS-CoV-2 infection begins to decrease over time following the initial doses of vaccination, and in association with the dominance of the delta variant, we are starting to see evidence of reduced protection against mild and moderate disease,\" the officials said in a statement . \n\n\n  The new plan to administer COVID-19 boosters to Americans is subject to evaluation from the Food and Drug Administration and a recommendation from a Centers for Disease Control and Prevention committee. \n\n\n  It does not apply to people who got the Johnson & Johnson $(JNJ)$ vaccine, only those who received the vaccines developed by Moderna $(MRNA)$ and Pfizer $(PFE)$. \n\n\n  Officials said individuals who got J&J's single-dose vaccine will likely need boosters, but they are waiting for data from the company in the coming weeks and then will set out a plan. \n\n\n  For the people who received the mRNA vaccines, boosters will begin to be available on Sept. 20. The first people to qualify for a third dose will include \"many health care providers, nursing home residents, and other seniors,\" then \"residents of long-term care facilities.\" \n\n\n  Related: Who can get a COVID booster shot, and where do you get one? Here's what we know so far  \n\n\n  The months-long debate about whether Americans who have been vaccinated will need an extra dose has been seemingly blunted by the rapid spread of the delta variant and the ensuing rise of cases, hospitalizations, and deaths in the U.S. over the last month or so. \n\n\n  Delta, which is more than twice as infectious as the original strain of the virus, is now estimated by the Centers for Disease Control and Prevention  to make up nearly 99% of all recent cases here. \n\n\n  \"Eight months after your second shot, get a booster shot,\" President Joe Biden said Wednesday . \"It will be easy. Just show your vaccination card and you'll get a booster -- no other ID, no insurance, no state residency requirement.\" \n\n\n  There are several factors at play in the booster discussion , but these are some of the most pressing questions: Do people who have been fully vaccinated actually need a boost? Is it ethical to give Americans a second or third dose when much of the world have no access to vaccines? Will Americans who have been told by federal health officials many times that boosters aren't needed listen this time? \n\n\n  When the U.S. last week said it would allow people who are immunocompromised to get an extra shot, officials repeated that boosters for the general public are not needed at this time . \n\n\n  \"We do not believe that others--elderly or non-elderly who are not immunocompromised--need a vaccine right at this moment, but this is a dynamic process and the data will be evaluated,\" Dr. Anthony Fauci, Biden's chief medical adviser, told reporters last Thursday. \n\n\n  That said, it's thought that immunity is waning among the vaccinated , and that's why we're hearing about more breakthrough infections, though those cases are still considered rare. \n\n\n  Texas Gov. Greg Abbott  is the most notable example this week of someone who is fully vaccinated who has also tested positive for the virus. \n\n\n  There is no federal tally of breakthrough cases, a decision that has been criticized by some pandemic experts , but some states are publicly sharing the data they have about these infections. \n\n\n  As of Aug. 8, 0.3% of Californians  that 0.2% people in the state--or 9,969 people out of the 4.3 million who have been fully vaccinated--have reported breakthrough infections, according to media reports. About 450 of those individuals were hospitalized, and 105 people died. \n\n\n  Don't miss from WSJ: As Delta surges, COVID-19 breakthrough cases remain uncommon  \n\n\n  Here's what the numbers say \n\n\n  The seven-day moving average is 128,347 cases per day and 553 deaths per day, as of Aug. 16, according to the latest data  from the Centers for Disease Control and Prevention. \n\n\n  August has been the worst month in 2021 for new cases since February, according to USA Today  found that there were more than 1,000 COVID-19 deaths on Tuesday. \n\n\n  About 168.9 million people  in the U.S., or 50.9% of the total population, are now fully vaccinated, as of Aug. 17, and 198.7 million, or 70.1%, of those who qualify for the vaccine, have received at least one shot. \n\n\n  Here's what else you need to know about COVID-19 \n\n\n  -- The U.S. extended the transit-related mask mandate  \n\n\n  -- COVID-19 vaccination rates are ticking up in Latin America, where it's more common for people to trust vaccines, according to The Wall Street Journal . In Chile and Uruguay, about two-thirds of the population in both countries are fully vaccinated. \n\n\n  -- Roche Holding AG said Actemra , its rheumatoid arthritis drug that recently received authorization in the U.S. as a COVID-19 treatment for hospitalized patients, is in short supply and will be so for weeks or months. The drug is being used around worldwide; however, demand for Actemra in the U.S. is \"well beyond 400% of pre-COVID levels over the last two weeks alone,\" the drug maker said Monday. Actemra, which is an IL-6 inhibitor, is one of the few therapies that has demonstrated its value as a COVID-19 treatment for the severely ill. \n\n\n  -Jaimy Lee \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  August 21, 2021 10:30 ET (14:30 GMT)\n\n\n  Copyright (c) 2021 Dow Jones & Company, Inc.","news_type":1},"isVote":1,"tweetType":1,"viewCount":299,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":832951205,"gmtCreate":1629565700607,"gmtModify":1676530071423,"author":{"id":"3579171197354301","authorId":"3579171197354301","name":"lyner","avatar":"https://static.tigerbbs.com/0b4cf00eeb2342a1bc5d6a42a6f98f6d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579171197354301","idStr":"3579171197354301"},"themes":[],"htmlText":"Like!","listText":"Like!","text":"Like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/832951205","repostId":"2161745182","repostType":2,"repost":{"id":"2161745182","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1629498169,"share":"https://ttm.financial/m/news/2161745182?lang=&edition=fundamental","pubTime":"2021-08-21 06:22","market":"us","language":"en","title":"COVID SCIENCE-Sugary molecules may be one way to prevent COVID; patients getting younger","url":"https://stock-news.laohu8.com/highlight/detail?id=2161745182","media":"Reuters","summary":"By Nancy Lapid   Aug 20 (Reuters) - Here is a summary of some recent studies on COVID-19. They inclu","content":"<html><body><p>By Nancy Lapid</p><p>   Aug 20 (Reuters) - Here is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.</p><p>   Sugar-molecule 'gates' help coronavirus infect cells</p><p>   Researchers have discovered a sugary residue on the spike of the novel coronavirus that helps it to break into cells and infect them, according to a study published in Nature Chemistry  on Thursday. The molecules that make up the sugary coating, called glycans, act as \"gates\" that open to let the spike's receptor-binding domain attach itself to a cell. Without this gate, the receptor-binding domain cannot take the shape it needs to break into the cell, Rommie Amaro of the University of California San Diego, who coauthored the study, said in a press statement. If drugs could be developed that \"lock\" the glycan gates closed, the virus would be prevented from entering and infecting cells, the researchers said.  </p><p>   COVID-19 patients were younger in early 2021 vs late 2020</p><p>   The average hospitalized COVID-19 patient was younger this past spring than last winter, researchers at a large Pennsylvania health system found. They analyzed data from nearly 39,000 COVID-19 patients, including 7,774 who were hospitalized. People who tested positive in March and April 2021, when the Alpha variant of the coronavirus was circulating, were younger and less likely to die compared to those diagnosed between November 2020 and January 2021. Among patients under 50, those who tested positive the spring were three times as likely to be hospitalized and twice as likely to require ICU admission or mechanical ventilation as those diagnosed in the winter before Alpha was widely circulating, according to a report posted on Wednesday on medRxiv  ahead of peer review. \"The widespread availability of highly effective vaccines holds promise,\" they said, \"but infections and deaths from the disease continue...This dynamic is particularly concerning in light of the continued emergence of novel SARS-CoV-2 variants.\"</p><p>   U.S. childbirth problems no worse during pandemic</p><p>   Problematic childbirths did not increase in the United States during the pandemic, researchers found in a study of nearly 838,500 women, including more than 225,000 who gave birth during the pandemic. There were no differences in rates of preterm birth, blood pressure problems in the mother, stillbirth, low birth weight, placenta problems, Cesarean deliveries, or uncontrolled bleeding after delivery, when comparing the March through December 2020 period to the pre-pandemic years of 2017 to 2019, the research team reported in Obstetrics &amp; Gynecology  Roughly half of the women had been tested for the coronavirus while pregnant, and about 7% of them had tested positive. There were no differences in childbirth outcomes between these groups. The authors were not able to distinguish between asymptomatic and symptomatic coronavirus infections, or severity of disease, which could have varying effects on pregnancy outcomes, or whether infection earlier or later in pregnancy made a difference. They only looked at labor and delivery outcomes, not at problems that might have occurred earlier in pregnancy. </p><p>    More nursing home data points to vaccine concerns</p><p>   Doctors who immunized 120 nursing home residents against COVID-19 with the Pfizer/BioNTech mRNA vaccine found protective antibodies in only 28% of the residents six months later, compared to 84% of residents immediately after full vaccination. The research, published on medRxiv  in advance of peer review, adds to evidence showing that protection from the vaccines wanes over time. Vaccinated healthcare workers had higher antibody levels than residents, which is not surprising because they were younger and healthier, but they too experienced \"significant declines\" in protection over time, the researchers reported. Given the \"rapid antibody decline\" and \"the rapid spread of the Delta variant and reports of vaccine breakthrough,\" they concluded that booster doses are probably needed. On Wednesday, the U.S. Centers for Disease Control and Prevention said it would \"begin efforts to deliver booster shots directly to residents of long-term care facilities,\" starting in September.</p><p>   Click for a Reuters graphic  on vaccines in development.</p><p>    &lt;^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ Tracking the vaccine race     COVID-19 Vaccination tracker    </p><p>   ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^&gt;</p><p>(Reporting by Nancy Lapid; Editing by Tiffany Wu)</p><p>((Nancy.Lapid@thomsonreuters.com))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID SCIENCE-Sugary molecules may be one way to prevent COVID; patients getting younger</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID SCIENCE-Sugary molecules may be one way to prevent COVID; patients getting younger\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-08-21 06:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>By Nancy Lapid</p><p>   Aug 20 (Reuters) - Here is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.</p><p>   Sugar-molecule 'gates' help coronavirus infect cells</p><p>   Researchers have discovered a sugary residue on the spike of the novel coronavirus that helps it to break into cells and infect them, according to a study published in Nature Chemistry  on Thursday. The molecules that make up the sugary coating, called glycans, act as \"gates\" that open to let the spike's receptor-binding domain attach itself to a cell. Without this gate, the receptor-binding domain cannot take the shape it needs to break into the cell, Rommie Amaro of the University of California San Diego, who coauthored the study, said in a press statement. If drugs could be developed that \"lock\" the glycan gates closed, the virus would be prevented from entering and infecting cells, the researchers said.  </p><p>   COVID-19 patients were younger in early 2021 vs late 2020</p><p>   The average hospitalized COVID-19 patient was younger this past spring than last winter, researchers at a large Pennsylvania health system found. They analyzed data from nearly 39,000 COVID-19 patients, including 7,774 who were hospitalized. People who tested positive in March and April 2021, when the Alpha variant of the coronavirus was circulating, were younger and less likely to die compared to those diagnosed between November 2020 and January 2021. Among patients under 50, those who tested positive the spring were three times as likely to be hospitalized and twice as likely to require ICU admission or mechanical ventilation as those diagnosed in the winter before Alpha was widely circulating, according to a report posted on Wednesday on medRxiv  ahead of peer review. \"The widespread availability of highly effective vaccines holds promise,\" they said, \"but infections and deaths from the disease continue...This dynamic is particularly concerning in light of the continued emergence of novel SARS-CoV-2 variants.\"</p><p>   U.S. childbirth problems no worse during pandemic</p><p>   Problematic childbirths did not increase in the United States during the pandemic, researchers found in a study of nearly 838,500 women, including more than 225,000 who gave birth during the pandemic. There were no differences in rates of preterm birth, blood pressure problems in the mother, stillbirth, low birth weight, placenta problems, Cesarean deliveries, or uncontrolled bleeding after delivery, when comparing the March through December 2020 period to the pre-pandemic years of 2017 to 2019, the research team reported in Obstetrics &amp; Gynecology  Roughly half of the women had been tested for the coronavirus while pregnant, and about 7% of them had tested positive. There were no differences in childbirth outcomes between these groups. The authors were not able to distinguish between asymptomatic and symptomatic coronavirus infections, or severity of disease, which could have varying effects on pregnancy outcomes, or whether infection earlier or later in pregnancy made a difference. They only looked at labor and delivery outcomes, not at problems that might have occurred earlier in pregnancy. </p><p>    More nursing home data points to vaccine concerns</p><p>   Doctors who immunized 120 nursing home residents against COVID-19 with the Pfizer/BioNTech mRNA vaccine found protective antibodies in only 28% of the residents six months later, compared to 84% of residents immediately after full vaccination. The research, published on medRxiv  in advance of peer review, adds to evidence showing that protection from the vaccines wanes over time. Vaccinated healthcare workers had higher antibody levels than residents, which is not surprising because they were younger and healthier, but they too experienced \"significant declines\" in protection over time, the researchers reported. Given the \"rapid antibody decline\" and \"the rapid spread of the Delta variant and reports of vaccine breakthrough,\" they concluded that booster doses are probably needed. On Wednesday, the U.S. Centers for Disease Control and Prevention said it would \"begin efforts to deliver booster shots directly to residents of long-term care facilities,\" starting in September.</p><p>   Click for a Reuters graphic  on vaccines in development.</p><p>    &lt;^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ Tracking the vaccine race     COVID-19 Vaccination tracker    </p><p>   ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^&gt;</p><p>(Reporting by Nancy Lapid; Editing by Tiffany Wu)</p><p>((Nancy.Lapid@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2161745182","content_text":"By Nancy Lapid   Aug 20 (Reuters) - Here is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.   Sugar-molecule 'gates' help coronavirus infect cells   Researchers have discovered a sugary residue on the spike of the novel coronavirus that helps it to break into cells and infect them, according to a study published in Nature Chemistry  on Thursday. The molecules that make up the sugary coating, called glycans, act as \"gates\" that open to let the spike's receptor-binding domain attach itself to a cell. Without this gate, the receptor-binding domain cannot take the shape it needs to break into the cell, Rommie Amaro of the University of California San Diego, who coauthored the study, said in a press statement. If drugs could be developed that \"lock\" the glycan gates closed, the virus would be prevented from entering and infecting cells, the researchers said.     COVID-19 patients were younger in early 2021 vs late 2020   The average hospitalized COVID-19 patient was younger this past spring than last winter, researchers at a large Pennsylvania health system found. They analyzed data from nearly 39,000 COVID-19 patients, including 7,774 who were hospitalized. People who tested positive in March and April 2021, when the Alpha variant of the coronavirus was circulating, were younger and less likely to die compared to those diagnosed between November 2020 and January 2021. Among patients under 50, those who tested positive the spring were three times as likely to be hospitalized and twice as likely to require ICU admission or mechanical ventilation as those diagnosed in the winter before Alpha was widely circulating, according to a report posted on Wednesday on medRxiv  ahead of peer review. \"The widespread availability of highly effective vaccines holds promise,\" they said, \"but infections and deaths from the disease continue...This dynamic is particularly concerning in light of the continued emergence of novel SARS-CoV-2 variants.\"   U.S. childbirth problems no worse during pandemic   Problematic childbirths did not increase in the United States during the pandemic, researchers found in a study of nearly 838,500 women, including more than 225,000 who gave birth during the pandemic. There were no differences in rates of preterm birth, blood pressure problems in the mother, stillbirth, low birth weight, placenta problems, Cesarean deliveries, or uncontrolled bleeding after delivery, when comparing the March through December 2020 period to the pre-pandemic years of 2017 to 2019, the research team reported in Obstetrics & Gynecology  Roughly half of the women had been tested for the coronavirus while pregnant, and about 7% of them had tested positive. There were no differences in childbirth outcomes between these groups. The authors were not able to distinguish between asymptomatic and symptomatic coronavirus infections, or severity of disease, which could have varying effects on pregnancy outcomes, or whether infection earlier or later in pregnancy made a difference. They only looked at labor and delivery outcomes, not at problems that might have occurred earlier in pregnancy.     More nursing home data points to vaccine concerns   Doctors who immunized 120 nursing home residents against COVID-19 with the Pfizer/BioNTech mRNA vaccine found protective antibodies in only 28% of the residents six months later, compared to 84% of residents immediately after full vaccination. The research, published on medRxiv  in advance of peer review, adds to evidence showing that protection from the vaccines wanes over time. Vaccinated healthcare workers had higher antibody levels than residents, which is not surprising because they were younger and healthier, but they too experienced \"significant declines\" in protection over time, the researchers reported. Given the \"rapid antibody decline\" and \"the rapid spread of the Delta variant and reports of vaccine breakthrough,\" they concluded that booster doses are probably needed. On Wednesday, the U.S. Centers for Disease Control and Prevention said it would \"begin efforts to deliver booster shots directly to residents of long-term care facilities,\" starting in September.   Click for a Reuters graphic  on vaccines in development.    <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ Tracking the vaccine race     COVID-19 Vaccination tracker       ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>(Reporting by Nancy Lapid; Editing by Tiffany Wu)((Nancy.Lapid@thomsonreuters.com))","news_type":1},"isVote":1,"tweetType":1,"viewCount":302,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836663525,"gmtCreate":1629476822767,"gmtModify":1676530055441,"author":{"id":"3579171197354301","authorId":"3579171197354301","name":"lyner","avatar":"https://static.tigerbbs.com/0b4cf00eeb2342a1bc5d6a42a6f98f6d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579171197354301","idStr":"3579171197354301"},"themes":[],"htmlText":"Like!","listText":"Like!","text":"Like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836663525","repostId":"2160071723","repostType":2,"isVote":1,"tweetType":1,"viewCount":125,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":836663825,"gmtCreate":1629476795267,"gmtModify":1676530055430,"author":{"id":"3579171197354301","authorId":"3579171197354301","name":"lyner","avatar":"https://static.tigerbbs.com/0b4cf00eeb2342a1bc5d6a42a6f98f6d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579171197354301","idStr":"3579171197354301"},"themes":[],"htmlText":"Like!","listText":"Like!","text":"Like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/836663825","repostId":"2160071723","repostType":2,"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838028384,"gmtCreate":1629360002648,"gmtModify":1676530014533,"author":{"id":"3579171197354301","authorId":"3579171197354301","name":"lyner","avatar":"https://static.tigerbbs.com/0b4cf00eeb2342a1bc5d6a42a6f98f6d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579171197354301","idStr":"3579171197354301"},"themes":[],"htmlText":"Interestinggg","listText":"Interestinggg","text":"Interestinggg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/838028384","repostId":"1161930198","repostType":2,"repost":{"id":"1161930198","pubTimestamp":1629331022,"share":"https://ttm.financial/m/news/1161930198?lang=&edition=fundamental","pubTime":"2021-08-19 07:57","market":"us","language":"en","title":"Investors compare 2021 stock-market rally to the pre-crash summer of 1987 — should they?","url":"https://stock-news.laohu8.com/highlight/detail?id=1161930198","media":"MarketWatch","summary":"‘Strength often begets strength,’ but there’s no guarantee\n'Wall Street' in the pre-working from hom","content":"<p>‘Strength often begets strength,’ but there’s no guarantee</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2d3b6031d3c2b32047dfe87035791cad\" tg-width=\"1050\" tg-height=\"708\" width=\"100%\" height=\"auto\"><span>'Wall Street' in the pre-working from home era. EVERETT COLLECTION</span></p>\n<p>Some investors are drawing parallels between the stock market’s 2021 climb and the pattern seen in 1987, a year that saw a seemingly relentless rally completely undone by the “Black Monday” crash in October, but there are some important differences, analysts note.</p>\n<p>Granted, the comparison does feel appropriate, at least on the surface, said Nicholas Colas, co-founder of DataTrek Research, in a Wednesday note.</p>\n<p>“Everyone, from plugged-in hedge-fund managers to retail investors, is making money. The movie ‘Wall Street’ debuted in late 1987 and, while this decade’s Bud Fox may be working from home, the overall societal vibe is similar.”</p>\n<p>But the comparison doesn’t look so apt when comparing the year-to-date performances of the S&amp;P 500 index,he said. The large-cap benchmark was up 36% through Aug. 17, 1987, versus just 18% for the same period in 2021.</p>\n<p>As for the two years prior, 1985 and 1986 saw S&amp;P 500 total returns of 31% and 18%, respectively, matching up identically with returns in 2019 and 2020 which Colas acknowledged is a bit “spooky.” However, he maintained, the 2021 rally is still a “pale comparison” to what was going on in 1987.</p>\n<p>Stocks were&nbsp;mostly lower&nbsp;on Wednesday, a day after the S&amp;P 500 and the Dow Jones Industrial Average&nbsp;each snapped a five-session streak of record finishes.</p>\n<p>Meanwhile, analysts at Bespoke Investment Group this week pointed out that the S&amp;P 500 is on pace to set a record for, well, records. Tuesday’s all-time closing high was not only the fifth in a row, it was also the 49th of 2021. That puts the index on track for 78 closing highs this year, which would edge out the record 77 seen in 1995.</p>\n<p>It’s no sure thing, the Bespoke analysts cautioned, noting that even a 5% pullback could eat into the ability to maintain a record-breaking pace. They noted that since 1950, there have been five years where the S&amp;P 500 had more than 40 record highs through Aug. 16, and while both 1995 and 1964 were the leaders in those years, years like 1987, 1997, and 1998 also had more than 40 record highs at this point in the year, and none of them finished the year with more than 50.</p>\n<p>But more important, what does such a rapid pace of closing highs mean for full-year performance? It’s mostly positive, as one would suspect, though there are exceptions, including, of course, 1987 (see table below).</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/981c0baa3da755be710dba80091eb0fd\" tg-width=\"1050\" tg-height=\"647\" width=\"100%\" height=\"auto\"><span>BESPOKE INVESTMENT GROUP</span></p>\n<p>The S&amp;P 500’s year-to-date gain is very similar to the median and average return of the five prior years in the table, the analysts noted.</p>\n<p>“Looking ahead, the median rest of year performance for the index from the close on 8/16 through year-end was a gain of 7.7% with positive returns four out of five times and more than doubling the average rest of year performance for all years since 1950,” they wrote, noting that “the one exception was in 1987 and it was a doozy.”</p>\n<p>So what should investors make of it all?</p>\n<p>The Bespoke analysts noted that the usual caveats apply — there’s no guarantee and past performance isn’t indicative of future results — but the data does underline the observation that “strength often begets strength in the market.”</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors compare 2021 stock-market rally to the pre-crash summer of 1987 — should they?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors compare 2021 stock-market rally to the pre-crash summer of 1987 — should they?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-19 07:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/investors-are-comparing-the-2021-stock-market-to-the-summer-of-1987-should-they-11629301481?mod=home-page><strong>MarketWatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>‘Strength often begets strength,’ but there’s no guarantee\n'Wall Street' in the pre-working from home era. EVERETT COLLECTION\nSome investors are drawing parallels between the stock market’s 2021 climb...</p>\n\n<a href=\"https://www.marketwatch.com/story/investors-are-comparing-the-2021-stock-market-to-the-summer-of-1987-should-they-11629301481?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".DJI":"道琼斯",".IXIC":"NASDAQ Composite"},"source_url":"https://www.marketwatch.com/story/investors-are-comparing-the-2021-stock-market-to-the-summer-of-1987-should-they-11629301481?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161930198","content_text":"‘Strength often begets strength,’ but there’s no guarantee\n'Wall Street' in the pre-working from home era. EVERETT COLLECTION\nSome investors are drawing parallels between the stock market’s 2021 climb and the pattern seen in 1987, a year that saw a seemingly relentless rally completely undone by the “Black Monday” crash in October, but there are some important differences, analysts note.\nGranted, the comparison does feel appropriate, at least on the surface, said Nicholas Colas, co-founder of DataTrek Research, in a Wednesday note.\n“Everyone, from plugged-in hedge-fund managers to retail investors, is making money. The movie ‘Wall Street’ debuted in late 1987 and, while this decade’s Bud Fox may be working from home, the overall societal vibe is similar.”\nBut the comparison doesn’t look so apt when comparing the year-to-date performances of the S&P 500 index,he said. The large-cap benchmark was up 36% through Aug. 17, 1987, versus just 18% for the same period in 2021.\nAs for the two years prior, 1985 and 1986 saw S&P 500 total returns of 31% and 18%, respectively, matching up identically with returns in 2019 and 2020 which Colas acknowledged is a bit “spooky.” However, he maintained, the 2021 rally is still a “pale comparison” to what was going on in 1987.\nStocks were mostly lower on Wednesday, a day after the S&P 500 and the Dow Jones Industrial Average each snapped a five-session streak of record finishes.\nMeanwhile, analysts at Bespoke Investment Group this week pointed out that the S&P 500 is on pace to set a record for, well, records. Tuesday’s all-time closing high was not only the fifth in a row, it was also the 49th of 2021. That puts the index on track for 78 closing highs this year, which would edge out the record 77 seen in 1995.\nIt’s no sure thing, the Bespoke analysts cautioned, noting that even a 5% pullback could eat into the ability to maintain a record-breaking pace. They noted that since 1950, there have been five years where the S&P 500 had more than 40 record highs through Aug. 16, and while both 1995 and 1964 were the leaders in those years, years like 1987, 1997, and 1998 also had more than 40 record highs at this point in the year, and none of them finished the year with more than 50.\nBut more important, what does such a rapid pace of closing highs mean for full-year performance? It’s mostly positive, as one would suspect, though there are exceptions, including, of course, 1987 (see table below).\nBESPOKE INVESTMENT GROUP\nThe S&P 500’s year-to-date gain is very similar to the median and average return of the five prior years in the table, the analysts noted.\n“Looking ahead, the median rest of year performance for the index from the close on 8/16 through year-end was a gain of 7.7% with positive returns four out of five times and more than doubling the average rest of year performance for all years since 1950,” they wrote, noting that “the one exception was in 1987 and it was a doozy.”\nSo what should investors make of it all?\nThe Bespoke analysts noted that the usual caveats apply — there’s no guarantee and past performance isn’t indicative of future results — but the data does underline the observation that “strength often begets strength in the market.”","news_type":1},"isVote":1,"tweetType":1,"viewCount":432,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":838023610,"gmtCreate":1629359906130,"gmtModify":1676530014488,"author":{"id":"3579171197354301","authorId":"3579171197354301","name":"lyner","avatar":"https://static.tigerbbs.com/0b4cf00eeb2342a1bc5d6a42a6f98f6d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579171197354301","idStr":"3579171197354301"},"themes":[],"htmlText":"Yesss","listText":"Yesss","text":"Yesss","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/838023610","repostId":"1156437638","repostType":2,"repost":{"id":"1156437638","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1629334625,"share":"https://ttm.financial/m/news/1156437638?lang=&edition=fundamental","pubTime":"2021-08-19 08:57","market":"us","language":"en","title":"3 Reasons Why Nio Is Rebounding From 6-Session Losing Streak","url":"https://stock-news.laohu8.com/highlight/detail?id=1156437638","media":"Benzinga","summary":"Nio, Inc. shares gained ground Wednesday, reversing course from the declines seen in the previous si","content":"<p><b>Nio, Inc.</b>&nbsp;shares gained ground&nbsp;Wednesday, reversing course from the declines seen in the previous six sessions.</p>\n<p><b>Earnings, Fatal Crash Pressure Nio Stock:</b>The electric vehicle stock began to lose ground ahead of the earnings report&nbsp;released Aug. 11 after the market close.</p>\n<p>The selling continued despite the company&nbsp;reporting&nbsp;forecast-beating headline numbers for the second quarter and issuing an upbeat guidance for the current quarter.</p>\n<p>The weakness was exacerbated by an accident involving a Nio ES8 all-electric SUV when it was in \"Navigate On Pilot\" mode. The owner of the vehicle was killed in the accident. The company was later accused of tampering with potentially incriminating vehicle data logs without the permission of traffic police.</p>\n<p>The string of losses resulted in Nio's shares losing about 16% of their&nbsp;market value.</p>\n<p><b>Trio Of Factors Lead To Wednesday's Recovery:</b>Ahead of Wednesday's rebound, Nio shares were trading in oversold territory. The stock held support around Wednesday's intraday low of $36.83, which cushioned any further downside.</p>\n<p>Secondly, Nio is feeding off on the across-the-board strength seen in the EV space. Nio's domestic peers&nbsp;<b>XPeng, Inc.</b>&nbsp;and&nbsp;<b>Li Auto, Inc.</b>&nbsp;are all in the green.</p>\n<p>XPeng announced Wednesday the start of a Phase 2 expansion project for the Zhaoqing smart EV manufacturing base, with the planned annual production capacity for the Zhaoqing Base to reach 200,000 units upon completion.</p>\n<p>EV leader&nbsp;<b>Tesla, Inc.</b>&nbsp;had its own share of troubles following the&nbsp;disclosure&nbsp;of a regulatory probe int&nbsp;its own autopilot program&nbsp;&nbsp;Monday. The stock, which extended its losses amid the development, is seen snapping a three-session losing streak.</p>\n<p>Thirdly, Nio's customers have rallied around the company amid the negative press on the fatal crash.</p>\n<p>\"We are well aware that NIO's NOP is currently an assisted driving system and not an autonomous or driverless system,\" a joint statement that has been signed by 500 owners said, the CnEVPost reported.</p>\n<p>\"NIO's presentation and promotion of NOP have not been confusing or misleading to us.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Reasons Why Nio Is Rebounding From 6-Session Losing Streak</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Reasons Why Nio Is Rebounding From 6-Session Losing Streak\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-19 08:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Nio, Inc.</b>&nbsp;shares gained ground&nbsp;Wednesday, reversing course from the declines seen in the previous six sessions.</p>\n<p><b>Earnings, Fatal Crash Pressure Nio Stock:</b>The electric vehicle stock began to lose ground ahead of the earnings report&nbsp;released Aug. 11 after the market close.</p>\n<p>The selling continued despite the company&nbsp;reporting&nbsp;forecast-beating headline numbers for the second quarter and issuing an upbeat guidance for the current quarter.</p>\n<p>The weakness was exacerbated by an accident involving a Nio ES8 all-electric SUV when it was in \"Navigate On Pilot\" mode. The owner of the vehicle was killed in the accident. The company was later accused of tampering with potentially incriminating vehicle data logs without the permission of traffic police.</p>\n<p>The string of losses resulted in Nio's shares losing about 16% of their&nbsp;market value.</p>\n<p><b>Trio Of Factors Lead To Wednesday's Recovery:</b>Ahead of Wednesday's rebound, Nio shares were trading in oversold territory. The stock held support around Wednesday's intraday low of $36.83, which cushioned any further downside.</p>\n<p>Secondly, Nio is feeding off on the across-the-board strength seen in the EV space. Nio's domestic peers&nbsp;<b>XPeng, Inc.</b>&nbsp;and&nbsp;<b>Li Auto, Inc.</b>&nbsp;are all in the green.</p>\n<p>XPeng announced Wednesday the start of a Phase 2 expansion project for the Zhaoqing smart EV manufacturing base, with the planned annual production capacity for the Zhaoqing Base to reach 200,000 units upon completion.</p>\n<p>EV leader&nbsp;<b>Tesla, Inc.</b>&nbsp;had its own share of troubles following the&nbsp;disclosure&nbsp;of a regulatory probe int&nbsp;its own autopilot program&nbsp;&nbsp;Monday. The stock, which extended its losses amid the development, is seen snapping a three-session losing streak.</p>\n<p>Thirdly, Nio's customers have rallied around the company amid the negative press on the fatal crash.</p>\n<p>\"We are well aware that NIO's NOP is currently an assisted driving system and not an autonomous or driverless system,\" a joint statement that has been signed by 500 owners said, the CnEVPost reported.</p>\n<p>\"NIO's presentation and promotion of NOP have not been confusing or misleading to us.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1156437638","content_text":"Nio, Inc. shares gained ground Wednesday, reversing course from the declines seen in the previous six sessions.\nEarnings, Fatal Crash Pressure Nio Stock:The electric vehicle stock began to lose ground ahead of the earnings report released Aug. 11 after the market close.\nThe selling continued despite the company reporting forecast-beating headline numbers for the second quarter and issuing an upbeat guidance for the current quarter.\nThe weakness was exacerbated by an accident involving a Nio ES8 all-electric SUV when it was in \"Navigate On Pilot\" mode. The owner of the vehicle was killed in the accident. The company was later accused of tampering with potentially incriminating vehicle data logs without the permission of traffic police.\nThe string of losses resulted in Nio's shares losing about 16% of their market value.\nTrio Of Factors Lead To Wednesday's Recovery:Ahead of Wednesday's rebound, Nio shares were trading in oversold territory. The stock held support around Wednesday's intraday low of $36.83, which cushioned any further downside.\nSecondly, Nio is feeding off on the across-the-board strength seen in the EV space. Nio's domestic peers XPeng, Inc. and Li Auto, Inc. are all in the green.\nXPeng announced Wednesday the start of a Phase 2 expansion project for the Zhaoqing smart EV manufacturing base, with the planned annual production capacity for the Zhaoqing Base to reach 200,000 units upon completion.\nEV leader Tesla, Inc. had its own share of troubles following the disclosure of a regulatory probe int its own autopilot program  Monday. The stock, which extended its losses amid the development, is seen snapping a three-session losing streak.\nThirdly, Nio's customers have rallied around the company amid the negative press on the fatal crash.\n\"We are well aware that NIO's NOP is currently an assisted driving system and not an autonomous or driverless system,\" a joint statement that has been signed by 500 owners said, the CnEVPost reported.\n\"NIO's presentation and promotion of NOP have not been confusing or misleading to us.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":160075870,"gmtCreate":1623767900790,"gmtModify":1703818836062,"author":{"id":"3579171197354301","authorId":"3579171197354301","name":"lyner","avatar":"https://static.tigerbbs.com/0b4cf00eeb2342a1bc5d6a42a6f98f6d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579171197354301","idStr":"3579171197354301"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FSM\">$Fortuna Silver Mines(FSM)$</a>hopefully it goes back up","listText":"<a href=\"https://laohu8.com/S/FSM\">$Fortuna Silver Mines(FSM)$</a>hopefully it goes back up","text":"$Fortuna Silver Mines(FSM)$hopefully it goes back up","images":[{"img":"https://static.tigerbbs.com/a7a279c83c21b2f6e4b95e3d7554bd3b","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160075870","isVote":1,"tweetType":1,"viewCount":426,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":160079244,"gmtCreate":1623767778488,"gmtModify":1703818827966,"author":{"id":"3579171197354301","authorId":"3579171197354301","name":"lyner","avatar":"https://static.tigerbbs.com/0b4cf00eeb2342a1bc5d6a42a6f98f6d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579171197354301","idStr":"3579171197354301"},"themes":[],"htmlText":"Interestingggg","listText":"Interestingggg","text":"Interestingggg","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/160079244","repostId":"2143075116","repostType":2,"isVote":1,"tweetType":1,"viewCount":285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":113687749,"gmtCreate":1622611060981,"gmtModify":1704187311608,"author":{"id":"3579171197354301","authorId":"3579171197354301","name":"lyner","avatar":"https://static.tigerbbs.com/0b4cf00eeb2342a1bc5d6a42a6f98f6d","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3579171197354301","idStr":"3579171197354301"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/HYLN\">$Hyliion Holdings Corp.(HYLN)$</a>it's moving","listText":"<a href=\"https://laohu8.com/S/HYLN\">$Hyliion Holdings Corp.(HYLN)$</a>it's moving","text":"$Hyliion Holdings Corp.(HYLN)$it's moving","images":[{"img":"https://static.tigerbbs.com/fc743e59285cde32a7c96ac70f7684a0","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":1,"link":"https://ttm.financial/post/113687749","isVote":1,"tweetType":1,"viewCount":692,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":true}